Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 3/20 | 0.61 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.61 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.61 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.61 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.61 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.61 |
| ▸ | APP | P05067 | 1/20 | 0.61 |
| ▸ | MME | P08473 | 2/20 | 0.56 |
| ▸ | REN | P00797 | 5/20 | 0.56 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27041288 | 1.00 | PSEN1 (0.61) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL23302438 | 1.00 | PSEN1 (0.61) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL14725527 | 1.00 | PSEN1 (0.61) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL28525267 | 0.93 | REN (0.59) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL28525268 | 0.93 | REN (0.59) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL28525265 | 0.93 | REN (0.59) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL22393402 | 0.92 | PSEN1 (0.67) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL17899496 | 0.91 | PSEN1 (0.63) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL11089707 | 0.90 | PSEN1 (0.61) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL20506597 | 0.90 | PSEN1 (0.58) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4629981-A2 | SMALL MOLECULE DEGRADERS OF C-SRC KINASE | The Regents Of The University Of Michigan (US) | 2025-10-15 | — | — | EP | claimed |
| WO-2024145315-A1 | TARGETED PROTEIN DEGRADERS OF INDOLEAMINE 2,3-DIOXYGENASE 1 (IDO1) | NORTHWESTERN UNIVERSITY (US) | 2024-07-04 | — | — | WO | claimed |
| WO-2024123819-A2 | SMALL MOLECULE DEGRADERS OF C-SRC KINASE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-06-13 | — | — | WO | claimed |
| US-20220023431-A1 | PROTEOLYSIS-TARGETING CHIMERIC MOLECULES (PROTACS) THAT INDUCE DEGRADATION OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) PROTEIN | NORTHWESTERN UNIVERSITY | 2022-01-27 | — | — | US | claimed |
| US-20260131010-A1 | MENIN PROTEOLYSIS TARGETING CHIMERAS (PROTACS) | UNIV TEXAS (US) | 2026-05-14 | — | — | US | disclosed |
| US-12492209-B2 | Substituted [1,2,4]triazolo[4,3-c]pyrimidines that induce degradation of embryonic ectoderm development (EED) protein | NORTHWESTERN UNIVERSITY (US) | 2025-12-09 | — | — | US | disclosed |
| US-12491252-B2 | Substituted 3-amino-5-phenylbenzamide compounds as covalent inhibitors of enhancer zeste homolog 2 (EZH2) and proteolysis-targeting chimeric derivatives thereof (PROTACs) that induce degradation of EZH2 | NORTHWESTERN UNIVERSITY (US) | 2025-12-09 | — | — | US | disclosed |
| EP-4629981-A2 | SMALL MOLECULE DEGRADERS OF C-SRC KINASE | The Regents Of The University Of Michigan (US) | 2025-10-15 | — | — | EP | disclosed |
| US-20250186434-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2025-06-12 | — | — | US | disclosed |
| US-12311029-B2 | Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein | NORTHWESTERN UNIVERSITY (US) | 2025-05-27 | — | — | US | disclosed |
| US-20250049930-A1 | PROTAC MOLECULES TARGETING FOXP3 AND USES THEREOF | CEDARS-SINAI MEDICAL CENTER (US) | 2025-02-13 | — | — | US | disclosed |
| EP-4460321-A2 | PROTAC MOLECULES TARGETING FOXP3 AND USES THEREOF | Cedars-Sinai Medical Center (US) | 2024-11-13 | — | — | EP | disclosed |
| CN-112125951-A | Impurities in ubenimex bulk drug and preparation method thereof | 深圳万乐药业有限公司 | 2020-12-25 | — | — | CN | disclosed |
| US-20200276176-A1 | COMPOUNDS FOR TARGETING MUTANT HUNTINGTIN PROTEIN AND USES THEREOF | CHDI FOUNDATION, INC. | 2020-09-03 | — | — | US | disclosed |
| US-20160193168-A1 | Treatment of Pulmonary Arterial Hypertension with Leukotriene Inhibitors | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2016-07-07 | — | — | US | disclosed |
| US-9233089-B2 | Treatment of pulmonary hypertension with leukotriene inhibitors | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-01-12 | — | — | US | disclosed |
| US-20130251787-A1 | Treatment of Pulmonary Hypertension with Leukotriene Inhibitors | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2013-09-26 | — | — | US | disclosed |
| US-4473554-A | Bestatin-related compounds as immunopotentiator | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1984-09-25 | — | — | US | disclosed |
| EP-0083931-A2 | New bestatin-related compounds as immunopotentiator | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1983-07-20 | — | — | EP | disclosed |
| US-4370318-A | Bestatin-related compounds as immunopotentiator | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1983-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12311029-B2 | Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein | IDO1, IDO2, KMO | PSEN1 2467/4885PSEN2 2909/4885APH1B 1392/4885 |
| US-20130251787-A1 | Treatment of Pulmonary Hypertension with Leukotriene Inhibitors | LTA4H, LTB4R2, LTB4R | PSEN1 4500/4885PSEN2 4665/4885APH1B 4315/4885 |
| US-20200276176-A1 | COMPOUNDS FOR TARGETING MUTANT HUNTINGTIN PROTEIN AND USES THEREOF | HTT, HYPK, UBQLN2 | PSEN1 212/4885PSEN2 95/4885APH1B 445/4885 |
| US-20260131010-A1 | MENIN PROTEOLYSIS TARGETING CHIMERAS (PROTACS) | CRBN, UBE3C, PSME3 | PSEN1 705/4885PSEN2 755/4885APH1B 684/4885 |
| US-12492209-B2 | Substituted [1,2,4]triazolo[4,3-c]pyrimidines that induce degradation of embryonic ectoderm development (EED) protein | EED, CUL3, PSME3 | PSEN1 2007/4885PSEN2 2587/4885APH1B 1524/4885 |
| US-20160193168-A1 | Treatment of Pulmonary Arterial Hypertension with Leukotriene Inhibitors | LTA4H, LTB4R2, LTB4R | PSEN1 4502/4885PSEN2 4680/4885APH1B 4170/4885 |
| US-20220023431-A1 | PROTEOLYSIS-TARGETING CHIMERIC MOLECULES (PROTACS) THAT INDUCE DEGRADATION OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) PROTEIN | IDO1, IDO2, KMO | PSEN1 2809/4885PSEN2 3170/4885APH1B 1816/4885 |
| US-12491252-B2 | Substituted 3-amino-5-phenylbenzamide compounds as covalent inhibitors of enhancer zeste homolog 2 (EZH2) and proteolysis-targeting chimeric derivatives thereof (PROTACs) that induce degradation of EZH2 | EZH2, BAZ2A, BAZ2B | PSEN1 1145/4885PSEN2 797/4885APH1B 1153/4885 |
| US-20250186434-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | SOS1, CUL1, SOS2 | PSEN1 266/4885PSEN2 742/4885APH1B 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.